Apolipoprotein A-II augments monocyte responses to LPS by suppressing the inhibitory activity of LPS-binding protein

Innate Immunity

Volumn 14, Issue 6, 2008, Pages 365-374

  Thompson, Patricia A ^a   Berbée, Jimmy F P ^b   Rensen, Patrick C N ^b   Kitchens, Richard L ^a,c  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^c NONE   (United States)

Author keywords

apoA II; Endotoxin; HDL; LBP; LPS

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN A2; APOLIPOPROTEIN C1; APOLIPOPROTEIN C3; APOLIPOPROTEIN E; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPOPOLYSACCHARIDE; LIPOPOLYSACCHARIDE BINDING PROTEIN; ACUTE PHASE PROTEIN; CARRIER PROTEIN; ENDOTOXIN; LIPOPOLYSACCHARIDE-BINDING PROTEIN; MEMBRANE PROTEIN; UNCLASSIFIED DRUG;

ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; FLUOROGRAPHY; HUMAN; HUMAN CELL; IMMUNE RESPONSE; INNATE IMMUNITY; LIPOPROTEIN BLOOD LEVEL; MONOCYTE; MOUSE; NONHUMAN; PROTEIN AGGREGATION; PROTEIN BINDING; PROTEIN PROTEIN INTERACTION; PROTEIN PURIFICATION; RABBIT; SEPSIS; WESTERN BLOTTING; WILD TYPE; ANIMAL; C57BL MOUSE; CELL LINE; CHEMISTRY; CHO CELL; CRICETULUS; DRUG ANTAGONISM; HAMSTER; IMMUNOLOGY; INFLAMMATION; METABOLISM;

MUS; ORYCTOLAGUS CUNICULUS;

ACUTE-PHASE PROTEINS; ANIMALS; APOLIPOPROTEIN A-II; CARRIER PROTEINS; CELL LINE; CHO CELLS; CHOLESTEROL, HDL; CRICETINAE; CRICETULUS; ENDOTOXINS; HUMANS; IMMUNITY, INNATE; INFLAMMATION; LIPOPOLYSACCHARIDES; MEMBRANE GLYCOPROTEINS; MICE; MICE, INBRED C57BL; MONOCYTES; PROTEIN BINDING; RABBITS;

EID: 58949091106     PISSN: 17534259     EISSN: 17534267     Source Type: Journal    
DOI: 10.1177/1753425908099171     Document Type: Article

References (43)

1. Poltorak A., He X., Smirnova I et al. Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: Mutations in Tlr4 gene. Science 1998; 282: 2085-2088.
2. Nagai Y., Akashi S., Nagafuku M. et al. Essential role of MD-2 in LPS responsiveness and TLR4 distribution. Nat Immunol 2002; 3: 667-672.
3. Schumann RR, Leong SR, Flaggs GW et al. Structure and function of lipopolysaccharide-binding protein. Science 1990; 249: 1429-1431.
4. Jack RS, Fan X., Bernhelden M. et al. Lipopolysaccharide-binding protein is required to combat a murine Gram-negative bacterial infection. Nature 1997; 389: 742-744.
5. Zweigner J., Schumann RR, Weber JR The role of lipopolysaccharide-binding protein in modulating the innate immune response. Microb Infect 2006; 8: 946-952.
6. Haziot A., Ferrero E., Köntgen F. et al. Resistance to endotoxin shock and reduced dissemination of Gram-negative bacteria in CD14-deficient mice. Immunity 1997; 4: 407-414.
7. Lamping N., Dettmer R., Schröder NW et al. LPS-binding protein protects mice from septic shock caused by LPS or Gram-negative bacteria. J Clin Invest 1998; 101: 2065-2071.
8. Yang KK, Dorner BG, Merkel U. et al. Neutrophil influx in response to a peritoneal infection with Salmonella is delayed in lipopolysaccharide-binding protein or CD14-deficient mice. J Immunol 2002; 169: 4475-4480.
9. Knapp S., de Vos AF, Florquin S., Golenbock DT, van der Poll T. Lipopolysaccharide binding protein is an essential component of the innate immune response to Escherichia coli peritonitis in mice. Infect Immun 2003; 71: 6747-6753.
10. Fan MH, Klein RD, Steinstraesser L. et al. An essential role for lipopolysaccharide-binding protein in pulmonary innate immune responses. Shock 2002; 18: 248-254.
11. Heumann D., Roger T. Initial responses to endotoxins and Gram-negative bacteria. Clin Chim Acta 2002; 323: 59-72.
12. Thompson PA, Kitchens RL Native high-density lipoprotein augments monocyte responses to lipopolysaccharide (LPS) by suppressing the inhibitory activity of LPS-binding protein. J Immunol 2006; 177: 4880-4887.
13. Zweigner J., Gramm HJ, Singer OC, Wegscheider K., Schumann RR High concentrations of lipopolysaccharide-binding protein in serum of patients with severe sepsis or septic shock inhibit the lipopolysaccharide response in human monocytes. Blood 2001; 98: 3800-3808.
14. Martin TR, Mathison JC, Tobias PS et al. Lipopolysaccharide binding protein enhances the responsiveness of alveolar macrophages to bacterial lipopolysaccharide. Implications for cytokine production in normal and injured lungs. J Clin Invest 1992; 90: 2209-2219.
15. Vreugdenhil ACE, Snoek AMP, Greve JW, Buurman WA Lipopolysaccharide-binding protein is vectorially secreted and transported by cultured intestinal epithelial cells and is present in the intestinal mucus of mice. J Immunol 2000; 165: 4561-4566.
16. Bannerman DD, Paape MJ, Hare WR, Sohn EJ Increased levels of LPS-binding protein in bovine blood and milk following bacterial lipopolysaccharide challenge. J Dairy Sci 2003; 86: 3128-3137.
17. Wurfel MM, Kunitake ST, Lichenstein H., Kane JP, Wright SD Lipopolysaccharide (LPS)-binding protein is carried on lipoproteins and acts as a cofactor in the neutralization of LPS. J Exp Med 1994; 180: 1025-1035.
18. Vesy CJ, Kitchens RL, Wolfbauer G., Albers JJ, Munford RS LPS binding protein and phospholipid transfer protein release lipopolysaccharides from Gram-negative bacterial membranes. Infect Immun 1999; 68: 2410-2417.
19. Gegner JA, Ulevitch RJ, Tobias PS Lipopolysaccharide (LPS) signal transduction and clearance. Dual roles for LPS binding protein and membrane CD14. J Biol Chem 1995; 270: 5320-5326.
20. Thompson PA, Tobias PS, Viriyakosol S., Kirkland TN, Kitchens RL Lipopolysaccharide (LPS)-binding protein inhibits responses to cell-bound LPS. J Biol Chem 2003; 278: 28367-28371.
21. Feingold KR, Funk JL, Moser AH, Shigenaga JK, Rapp JH, Grunfeld C. Role for circulating lipoproteins in protection from endotoxin toxicity. Infect Immun 1995; 63: 2041-2046.
22. Barlage S., Fröhlich D., Böttcher A. et al. ApoE-containing high density lipoproteins and phospholipid transfer protein activity increase in patients with a systemic inflammatory response. J Lipid Res 2001; 42: 281-290.
23. Kitchens RL, Thompson PA, Munford RS, O'Keefe GE Acute inflammation and infection maintain circulating phospholipid levels and enhance lipopolysaccharide binding to plasma lipoproteins. J Lipid Res 2003; 44: 2339-2348.
24. Berbée JFP, van der Hoogt CC, de Haas CJC et al. Plasma apolipoprotein CI correlates with increased survival in patients with severe sepsis. Intensive Care Med 2008; 34: 907-911.
25. Li L., Thompson PA, Kitchens RL Infection induces a positive acute phase apolipoprotein E response from a negative acute phase gene: Role of hepatic LDL receptors. J Lipid Res 2008; 49: 1782-1793.
26. Berbée JFP, van der Hoogt CC, Kleemann R. et al. Apolipoprotein CI stimulates the response to lipopolysaccharide and reduces mortality in Gram-negative sepsis. FASEB J 2006; 20: 2162-2164.
27. Kitchens RL, Wolfbauer G., Albers JJ, Munford RS Plasma lipoproteins promote the release of bacterial lipopolysaccharide from the monocyte cell surface. J Biol Chem 1999; 274: 34116-34122.
28. Weng W., Breslow J. Dramatically decreased high density lipoprotein cholesterol, increased remnant clearance, and insulin hypersensitivity in apolipoprotein A-II knockout mice suggest a complex role for apolipoprotein A-II in atherosclerosis susceptibility. Proc Natl Acad Sci USA 1996; 93: 14788-14794.
29. Munford RS, DeVeaux LC, Cronan Jr JE, Rick PD Biosynthetic radiolabeling of bacterial lipopolysaccharide to high specific activity. J Immunol Methods 1992; 148: 115-120.
30. Emancipator K., Csako G., Elin RJ In vitro inactivation of bacterial endotoxin by human lipoproteins and apolipoproteins. Infect Immun 1992;60: 596-601.
31. Flegel WA, Baumstark MW, Weinstock C., Berg A., Northoff H. Prevention of endotoxin-induced monokine release by human low- and high-density lipoproteins and by apolipoprotein A-I. Infect Immun 1993; 61: 5140-5146.
32. Ma J., Liao X. -L, Lou B., Wu M-P. Role of apolipoprotein A-I in protecting against endotoxin toxicity. Acta Biochim Biophys Sin 2004; 36: 419-424.
33. Rensen PCN, Van Oosten M., Van de Bilt E., Van Eck M., Kuiper J., Van Berkel TJC. Human recombinant apolipoprotein E redirects lipopolysaccharide from Kupffer cells to liver parenchymal cells in rats in vivo. J Clin Invest 1997; 99: 2438-2445.
34. Blanco-Vaca F., Escola-Gil JC, Martin-Campos JM, Julve J. Role of apoA-II in lipid metabolism and atherosclerosis: Advances in the study of an enigmatic protein. J Lipid Res 2001; 42: 1727-1739.
35. Lenich C., Brecher P., Makrides S., Chobanian A., Zannis VI Apolipoprotein gene expression in the rabbit: Abundance, size, and distribution of apolipoprotein mRNA species in different tissues. J Lipid Res 1988; 29: 755-764.
36. Munford RS, Hall CL, Dietschy JM Binding of Salmonella typhimurium lipopolysaccharides to rat high-density lipoproteins. Infect Immun 1981; 34: 835-843.
37. Recalde D., Ostos MA, Badell E. et al. Human apolipoprotein A-IV reduces secretion of proinflammatory cytokines and atherosclerotic effects of a chronic infection mimicked by lipopolysaccharide. Arterioscler Thromb Vasc Biol 2004; 24: 756-761.
38. Mueller M., Lindner B., Kusumoto S., Fukase K., Schromm AB, Seydel U. Aggregates are the biologically active units of endotoxin. J Biol Chem 2004; 279: 26307-26313.
39. Hailman E., Lichenstein HS, Wurfel MM et al. Lipopolysaccharide (LPS)-binding protein accelerates the binding of LPS to CD14. J Exp Med 1994; 179: 269-277.
40. Gioannini TL, Teghanemt A., Zhang D. et al. Isolation of an endotoxin-MD-2 complex that produces Toll-like receptor 4-dependent cell activation at picomolar concentrations. Proc Natl Acad Sci USA 2004; 101: 4186-4191.
41. Massamiri T., Tobias PS, Curtiss LK Structural determinants for the interaction of lipopolysaccharide binding protein with purified high density lipoproteins: Role of apolipoprotein A-I. J Lipid Res 1997; 38: 516-525.
42. Wurfel MM, Monks BG, Ingalls RR et al. Targeted deletion of the lipopolysaccharide (LPS)-binding protein leads to profound suppression of LPS responses ex vivo, whereas in vivo responses remain intact. J Exp Med 1997; 186: 2051-2056.
43. Castellani LW, Navab M., Van Lenten BJ et al. Overexpression of apolipoprotein AII in transgenic mice converts high density lipoproteins to proinflammatory particles. J Clin Invest 1997; 100: 464-474.